GlassScriptPhysician profile
Lindsay Daly
NPI 1780356972
$7,579.96
in general payments reported to CMS, 2019-2025
23 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.31 · 2022: $1,568 · 2023: $2,634 · 2024: $2,849 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,641 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,640.55 |
| Education | $316.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.38 | 2021-2025 | |
| Leo Pharma INC. | $1,114.99 | 2022-2025 | Adbry |
| Lilly USA, LLC | $629.63 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $597.61 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $517.66 | 2023-2024 | Vtama |
| Incyte Corporation | $413.55 | 2021-2025 | Opzelura |
| Genzyme Corporation | $359.98 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $352.43 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $350.73 | 2022-2024 | Ilumya |
| Ucb, INC. | $279.42 | 2022-2024 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $273.57 | 2022-2023 | |
| Amgen INC. | $268.31 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $236.52 | 2022-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $205.41 | 2022-2024 | Jublia, Arazlo, Duobrii |
| Pfizer INC. | $184.22 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $177.32 | 2022-2024 | Aklief |
| Organogenesis INC. | $162.73 | 2023-2024 | Puraply, Puraply Am |
| Arcutis Biotherapeutics, INC. | $86.10 | 2023-2025 | Zoryve |
| Strata Skin Sciences, INC. | $24.14 | 2023 | Xtrac |
| Epi Health, LLC | $19.84 | 2022 | |
| Glaxosmithkline, LLC. | $14.70 | 2025 | Nucala |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $10.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.